Slingshot members are tracking this event:
Dermira (DERM) Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
Slingshot Insights Explained
Jan 31, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 2b, Lebrikizumab, Atopic Dermatitis